[1] |
杨艳玲, 叶军. 高苯丙氨酸血症的诊治共识[J], 中华儿科杂志, 2014, 52(6): 420-425.
|
[2] |
中华人民共和国卫生部. 苯丙酮尿症和先天性甲状腺功能减低症诊治技术规范[卫妇社发(96)号][J]. 中国儿童保健杂志, 2011, 19(2): 190-191.
|
[3] |
Shintaku H. Disorders of tetrahydrobiopterin metabolism and their treatment[J]. Curr Drug Metab, 2002, 3(2): 123-131.
doi: 10.2174/1389200024605145
pmid: 12003346
|
[4] |
Anikster Y, Haack TB, Vilboux T, et al. Biallelic mutations in DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual disability[J]. Am J Hum Genet, 2017, 100(2): 257-266.
doi: S0002-9297(17)30002-2
pmid: 28132689
|
[5] |
van Spronsen FJ, Blau N, Harding C, et al. Phenylketonuria[J]. Nat Rev Dis Primers, 2021, 7(1): 36.
doi: 10.1038/s41572-021-00267-0
pmid: 34017006
|
[6] |
顾学范. 苯丙氨酸羟化酶缺乏症饮食治疗与营养管理共识[J]. 中华儿科杂志, 2019, 57(6): 405-409.
|
[7] |
Fanet H, Capuron L, Castanon N, et al. Tetrahydrobloterin (BH4) pathway: from metabolism to neuropsychiatry[J]. Curr Neuropharmacol, 2021, 19(5): 591-609.
|
[8] |
Singh RH, Rohr F, Frazier D, et al. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency[J]. Genet Med, 2014, 16(2): 121-131.
doi: 10.1038/gim.2013.179
pmid: 24385075
|
[9] |
Ye J, Yang Y, Yu W, et al. Demographics, diagnosis and treatment of 256 patients with tetrahydrobiopterin deficiency in mainland China: results of a retrospective, multicentre study[J]. J Inherit Metab Dis, 2013, 36(5): 893-901.
doi: 10.1007/s10545-012-9550-6
pmid: 23138986
|
[10] |
Gu X, Wang Z, Ye J, et al. Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening[J]. Ann Acad Med Singap, 2008, 37(< W>12 Suppl): 107-104.
|
[11] |
Blau N, Burton BK, Thöny B, et al. UNI-MED Verlag AG, 2010, 10-12.
|
[12] |
Anjema K, van Rijn M, Hofstede FC, et al. Tetra-hydrobiopterin responsiveness in phenylketonuria: prediction with the 48-hour loading test and genotype[J]. Orphanet J Rare Dis, 2013, 8: 103.
doi: 10.1186/1750-1172-8-103
pmid: 23842451
|
[13] |
Liu N, Huang Q, Li Q, et al. Spectrum of PAH gene variants among a population of Han Chinese patients with phenylketonuria from northern China[J]. BMC Med Gene, 2017, 18(1): 108.
|
[14] |
Yan YS, Yao FX, Hao SJ, et al. Analysis of large deletion of phenylalanine hydroxylase gene in Chinese patients with phenylketonuria[J]. Zhonghua Yi Xue Za Zhi, 2016, 96(14): 1097-1102.
|
[15] |
Blau N, Hennermann JB, Langenbeck U, et al. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies[J]. Mol Genet Metab, 2011, 104 (Suppl): S2-S9.
|
[16] |
Sakai N. Guides for tetrahydrobiopterin-responsive hyperphenylalaninemia[J]. Pediatr Int, 2021, 63(1): 7.
doi: 10.1111/ped.14505
pmid: 33486873
|
[17] |
Zhu T, Qin S, Ye J, et al. Mutational spectrum of phenylketonuria in the Chinese Han population: a novel insight into the geographic distribution of the common mutations[J]. Pediatr Res, 2010, 67(3): 280-285.
doi: 10.1203/PDR.0b013e3181c9fb85
pmid: 19915519
|
[18] |
张知新, 喻唯民, 王琳, 等. 四氢生物喋呤缺乏症治疗前后神经系统表现及其脑白质病变分析[J]. 临床儿科杂志, 2005, 23(1): 101-104.
|
[19] |
Sundermann B, Pfleiderer B, Möller HE, et al. Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients[J]. J Inherit Metab Dis, 2011, 34(3): 711-721.
doi: 10.1007/s10545-011-9318-4
pmid: 21491106
|
[20] |
MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment[J]. Orphanet J Rare Dis, 2017, 12(1): 162.
doi: 10.1186/s13023-017-0685-2
pmid: 29025426
|
[21] |
Utz JR, Lorentz CP, Markowitz D, et al. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients[J]. Mol Genet Metab, 2012, 105(2): 193-197.
doi: 10.1016/j.ymgme.2011.10.014
pmid: 22112818
|
[22] |
Shintaku H, Ohura T, Takayanagi M, et al. Guide for diagnosis and treatment of hyperphenylalaninemia[J]. Pediatr Int, 2021, 63(1): 8-12.
doi: 10.1111/ped.14399
pmid: 33423362
|
[23] |
Li M, Yang Q, Yi S, et al. Two novel mutations in DNAJC12 identified by whole-exome sequencing in a patient with mild hyperphenylalaninemia[J]. Mol Genet Genomic Med, 2020, 8(8): e1303.
|
[24] |
Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline[J]. Genet Med, 2014, 16(2): 188-200.
doi: 10.1038/gim.2013.157
pmid: 24385074
|
[25] |
Singh RH, Cunningham AC, Mofidi S, et al. Updated, web-based nutrition management guideline for PKU: an evidence and consensus based approach[J]. Mol Genet Metab, 2016, 118(2): 72-83.
doi: 10.1016/j.ymgme.2016.04.008
pmid: 27211276
|
[26] |
Yano S, Moseley K, Azen C. Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker[J]. J Pediatr, 2013, 162(5): 999-1003.
doi: 10.1016/j.jpeds.2012.10.015
|
[27] |
Gupta S, Lau K, Harding CO, et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials[J]. EBioMedicine, 2018, 37, 366-373 (2018).
doi: S2352-3964(18)30456-0
pmid: 30366815
|
[28] |
MacLeod EL, Clayton MK, van Calcar SC, et al. Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria[J]. Mol Genet Metab, 2010, 100(4):303-308.
doi: 10.1016/j.ymgme.2010.04.003
pmid: 20466571
|
[29] |
Levy HL, Sarkissian CN, Scriver CR. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria[J]. Mol Genet Metab, 2018, 124(4): 223-229.
doi: S1096-7192(18)30292-0
pmid: 29941359
|